Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConvertible DebtCurrent AssetsCurrent LeasesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Apellis Pharmaceuticals (APLS) Other Non-Current Liabilities (2020 - 2025)

Historic Other Non-Current Liabilities for Apellis Pharmaceuticals (APLS) over the last 6 years, with Q3 2025 value amounting to $3.3 million.

  • Apellis Pharmaceuticals' Other Non-Current Liabilities fell 6686.34% to $3.3 million in Q3 2025 from the same period last year, while for Sep 2025 it was $3.3 million, marking a year-over-year decrease of 6686.34%. This contributed to the annual value of $8.0 million for FY2024, which is 24480.97% up from last year.
  • Per Apellis Pharmaceuticals' latest filing, its Other Non-Current Liabilities stood at $3.3 million for Q3 2025, which was down 6686.34% from $2.1 million recorded in Q2 2025.
  • Over the past 5 years, Apellis Pharmaceuticals' Other Non-Current Liabilities peaked at $345.2 million during Q4 2021, and registered a low of $347000.0 during Q1 2023.
  • Moreover, its 5-year median value for Other Non-Current Liabilities was $2.5 million (2023), whereas its average is $67.3 million.
  • Per our database at Business Quant, Apellis Pharmaceuticals' Other Non-Current Liabilities plummeted by 9955.05% in 2022 and then soared by 93900.63% in 2024.
  • Apellis Pharmaceuticals' Other Non-Current Liabilities (Quarter) stood at $345.2 million in 2021, then tumbled by 99.44% to $1.9 million in 2022, then rose by 19.3% to $2.3 million in 2023, then soared by 244.81% to $8.0 million in 2024, then tumbled by 59.14% to $3.3 million in 2025.
  • Its Other Non-Current Liabilities stands at $3.3 million for Q3 2025, versus $2.1 million for Q2 2025 and $2.1 million for Q1 2025.